OldAimGuy,

In my opinion, you have a very well thought out approach to playing the ups and downs which regularly occur with EPD. I have done similar, but perhaps not as often and not to the same degree. My intention was to find a well managed company that could weather the economic storms and remain healthy --- EPD fits that description for me. I also see that EPD supplies a "must have" product that people cannot live without (at least, at the current time).

I envy you for picking up shares down at $16.79. I thought the $19.00 range was an excellent buy, and if it hits that point again, I will certainly buy more. I also re-invest my dividend, but I wait till the price drops before doing so (usually about a month and a half after the dividend pay date).

Thanks for posting. I don't post often, but enjoy hearing about experience of others. Best wishes.

Kgem

Enterprise Products Partners L.P. showed some pretty healthy financials this quarter. The following are a few of the highlights:

Enterprise Products Partners brought in total revenue of $15.468 billion in the third quarter of 2022. This represents a 42.80% increase over the $10.832 billion that the company brought in during the prior-year quarter.

The company reported an operating income of $1.712 billion in the current quarter. This compares quite favorably to the $1.513 billion that the company reported in the year-ago quarter.

Enterprise Products Partners transported an average of 17.5 trillion BTU of natural gas per day through its pipeline infrastructure in the reporting period. This represents a 19.86% increase over the 14.6 trillion BTU of natural gas per day that the company averaged during the equivalent quarter of last year.

The company reported a distributable cash flow of $1.868 billion in the most recent quarter. This represents a 15.81% increase compared to the $1.613 billion that the company reported last year.

Enterprise Products Partners reported a net income attributable to the common unitholders of $1.360 billion in the third quarter of 2022. This represents a 17.95% increase over the $1.153 billion that the company reported in the third quarter of 2021.

In my opinion, EPD is a buy and hold. And, while we wait for policy makers to wake up to the need for a multi-pronged energy approach, we get paid a dividend that is tax free. As a retired senior, that additional income is worth its weight in gold.

US crude, gasoline and distillate stockpiles all declined last week, according to the Energy Information Administration, adding to a tightening supply outlook. Motor fuel inventories tumbled by 4.73 million barrels to the lowest level since November 2014.

“All the developments we have seen on the supply side at this point very much sets the stage for what we believe will be higher prices into the end of this year,” Damien Courvalin, the head of energy research at Goldman Sachs, said in a Bloomberg television interview. “With this cut and the winter seasonal demand, inventories will continue to fall.”

Data suggests oil will climb to $100 per barrel sooner than had been expected.


Source: EnergyNow.com

Enterprise Products Partners is going up steadily, and when you look at the horizon, many things could happen that would likely drive the price even higher. If a single Hurricane were to enter the Gulf Of Mexico, and approach the United States coast, I suspect share price would jump considerably. Also, a cold winter in Europe would make natural gas go higher. Of course, a nuclear deal with Iran would put much more oil and gas on the market, and that is a negative. Also, the United States and the rest of the world may enter a full scale recession that might last for years and that too could drive prices lower. Inflation, on the other hand, drives prices higher.

In my opinion, the world will need oil and gas for many years to come, and that bodes well for EPD investors. The good thing is we are paid a nice dividend every single quarter while we wait, and that reduces our cost average every single quarter. If one reinvests those dividends, the return is even higher. This means EPD is a relatively safe way to invest and build personal wealth, or a great way to supplement one's income tax free every single quarter.

North American liquefied natural gas (LNG) developers and producers this year have struck deals to sell 48 million tonnes of LNG, which will eventually pump up exports 60% from current levels, although much of the output remains years away.
LNG demand is soaring as the conflict in Ukraine pushes global prices to their highest in at least 14 years. Buyers in Europe have looked West in a move away from Russian gas, and Chinese buyers are striking long-term deals after a pause.

Eight North American LNG export terminals are under construction and over a dozen more could receive financial greenlights by 2023. Some buyers have locked in supplies from plants that have not yet been approved for construction, so not every supply agreement may go ahead.

This week, European gas prices hit $84 per million British thermal units (mmBtu) and U.S. gas futures on Tuesday topped $10 per mmBtu for the first time since 2008.

Goldman Sachs forecasts global LNG demand to rise about 12% 424 MTPA next year and expects new plants that will supply 156 MTPA to be approved within the next five years.
Growing demand has made the United States this year’s largest LNG exporting nation during the first six months. Approved projects that are expected to begin shipments between 2023-2026 could keep the country in first place.

“The global energy crisis has been years in the making due to significant underinvestment,” said Octavio Simoes, CEO of Tellurian, which recently started construction on its long-delayed plant in Louisiana.



SOURCE: https://energynow.com/2022/08/north-american-firms-make-deals-to-boost-lng-exports

Four press releases this morning just may end the doldrums also. Just catching up on what they all say right now.

Joe Biden and the Dems are likely to be in trouble this November because of inflation. The administration could reduce inflation by once again opening up America to drilling, pipelines, and exploration. Their solution: Producing more biofuels --- news flash, we are already experiencing food and supply shortages.

Dividend stocks are a hedge against high inflation, and Enterprise Products Partners is a high dividend stock. If you think fuel prices are high now, just wait until the summer driving season starts. People have been shut in their homes for a couple of years because of the pandemic --- the question is will they continue to stay at home because of inflation? I don't think so. People need to get out and start living.

In my opinion, the lack of investment in the oil and gas industry will eventually lead to a oil and gas industry super cycle --- a cycle that we are only just beginning to see. It looks to me like EPD is a great place to be, and shareholders are actually paid to be here. My two cents for what that is worth.

So today we hear that analysts are neutral on Enterprise Products Partners. I guess I would be neutral too based on the fact there is still no change of direction for our current administration. Biden spoke to voters in Iowa (where a bird pooped on him while he was blaming Putin for the high inflation), and he said he was doing everything in his power to help the farmers. Apparently, Biden feels that increasing corn derived fuel will help the farmers. Does anyone know what is required for corn production --- fuel and fertilizer are key components.

Enterprise Products Partners appears to be ideally positioned for continuous growth even in the current political environment --- See the presentation now out on EPD's website. EPD's existing pipelines are positioned in ideal locations to capture additional transport volume, and this includes carbon capture which is likely to be a major part of future legislation and/or executive orders. If the US decides to supply LNG to Europe, EPD has the ability to do so and in large volume. However, additional pipeline permitting will likely be needed. The question is: will this administration balance the needs of European LNG with their current anti-fossil fuel goals.

Pete807, normally I would not ask this question on an open forum, but I do not have PM on IHUB. Can you tell me if there are any special tax benefits from being invested in a Master Limited Partnership. In particular, can I deduct expenses for such things as a computer needed for trading? Thank you in advance.


Kgem

It is no wonder people cannot stand you pots. You are so negative that no one wants to invest in LXRP any more. So, good job. You have been successful destroying the value people thought they had when they invested in LXRP. I applaud you. Maybe if you could pull your head out of the sand you just might find something good to post, but I doubt it.

Chris did in fact buy more shares. I wonder who first broke this news? He never did say when he would buy them, but that he intended to do so.

Thank you Lanny9 for your civilized post. There is so much going on behind the scenes, but little discussion of it on this board. The press release today is huge --- particularly for European markets. Yet, some talk about a reverse split on this forum that was only mentioned as a last resort if needed to get to a major exchange. I still suggest that Chris is looking at the Amex and nothing lower, but who knows for certain.

The products coming from BAT are in the works right now, and Altria is out in the cold. In my opinion, Altria was not a particularly good deal for LXRP, but the money for research did help greatly.

While I am currently underwater with my first shares, I intend to stick with this investment, and buy even more. Some may think the share price will go further down, but I think the price is going higher. We will see who is right soon enough. I really don't care about short term loses or gains because I am investing in a disruptive technology.



Kgem

Ya Gaffer, you and Pots seem to run the LXRP board, and the type of posts here seem to revolve around your thought patterns. I am done with you. So much for an open forum.

That is fine Gaffer. I suggest some of the complainers actually contact the CEO and talk to him themselves. But I will say this, if all I ever did was sit around and wait for official news, I would never make any money on the OTC. Instead, I would be a penny stock loser like many are.

It is your money, make your own decisions, and do your own due diligence. If you don't want to hear others who do their own due diligence, then there will never be a conversation or an exchange of ideas on this forum. Something to think about.

Pots, once again you say I am posting HEARSAY. Yet I contacted the CEO and this is what I was told and where I got the information. So, for me, this is not hearsay. Is English your first language?

I cannot confirm (at this time) if Chris told me the truth. But I did reach out to him. I did not just park my butt on this forum and complain all day long.

What you are doing Pots, is the reason few people are posting. Maybe you should look inward. LXRP is putting out information as they can, but non-disclosure agreements prevent them from telling us everything.

Gaffer, I can only tell you what Chris told me. The how, the when, and the price paid are not something I know. The only reason I posted was because I seen how negative the posting was on this forum, and thought it might help to post what I learned. I am not interested in pumping, and I don't care at all if people buy or sell. This looks to me to be a good long term investment, but like has already been stated, staying invested depends on what happens.

There were people on this forum who complained that Chris was not buying shares. If what he told me is true, then that question has been answered. And, when the CEO is buying, I find that it is generally done for a very good reason.

Lanny9, that is a well thought out post. I certainly will not tell you how to play this, but your thought process is sound. Keeping in mind that reverse splits are common at this end of the market, one must always be concerned. However, time is quickly running out if Chris does intend to up-list as early as December. Again, how do we get to the required price per share? The back and forth between R/S and then dilution could happen, but that takes time and a lot public disclosures. If true, it would seem we would be in for a very volatile period. The problem I see is that the price must be maintained for at least one month. So dilution would likely need to happen next year.

I don't owe you anything at all do I Pots? I recently talked to Chris and he told me he is increasing his share ownership in Lexaria to 21% (that was about two weeks ago). So either Chris lied to me, or you don't know what is going on, or perhaps both. Chris is very positive about the future of the company. The recent interview posted on this board points to great progress as well. So where do you get off talking like you are in the know? You clearly don't seem to know anything about the company you claim to own shares in. Why don't you try calling Chris if you have such great concerns?

And your post clearly indicates you do not understand the term liquidity.

I can read the same as you Pots. One requirement for trading on a major exchange is liquidity. Since Chris already owns 21% of the shares, a R/S of just 2 shares for one would basically give Chris full control of the company and he could take the company private. However, that is not what Chris claims he wants to do. So explain to me how a R/S can get us to where we want to be? Chris would have to take us down to hardly any shares at all to meet the required share price.

Since this board is for opinion, and not dogma, I suggest business news showing increased revenue is basically the only way to reach the desired share price. And, Chris states we could up-list in December. So a lot of news may soon be coming our way. In my opinion of course.



Nasdaq Global Select Market Listing Requirements:

Requirements Standard 1: Earnings Standard 3: Capitalization with Revenue
Market Value of Publicly Held Securities(1) $45,000,000 $45,000,000
# of Shares Publicly Held(2) 1,250,000 1,250,000
# Public Board Lot Holders 450 450
Trading Price of Listed Securities(2) $4.00 $4.00


Personally, I suspect Chris will go to the Amex, but I will use the NASDAQ because the requirements are less.

You may be right Gaffer. This is positive news, so the share price may increase. However, I am not convinced Chris will do a reverse split. I suspect a R/S was voted on as a way of protecting themselves from a hostile takeover. In my opinion, any kind of up-list will require a lot more liquidity, and a R/S will only reduce that liquidity.

$LXRP ---

NEWS RELEASE: 10/21/2020

Lexaria Bioscience Granted First European Patent for DehydraTECHTM Technology


New patent includes method of treatment claims for a broad range of disease conditions including use of:
cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer’s and Parkinson’s
cannabinoids to treat metabolic disorders and substance abuse and addictions
nicotine to treat tobacco dependence/addiction and neurological diseases
NSAIDs to treat a host of conditions involving pain, fever and inflammatory states
vitamins to treat conditions such as ataxia related to certain vitamin deficiencies 
Kelowna, British Columbia – October 21, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM Technology.

European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” and includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and vitamins.  

In addition, this patent includes important method of treatment claims for a broad range of disease conditions including use of:
cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer’s and Parkinson’s;
cannabinoids to treat metabolic disorders and substance abuse and addictions;
nicotine to treat tobacco dependence/addiction and neurological diseases;
NSAIDs to treat a host of conditions involving pain, fever and inflammatory states; and,
vitamins to treat conditions such as ataxia related to certain vitamin deficiencies. 
Priority is granted to certain dates in 2014 and 2015, strengthening Lexaria’s IP claims compared to more recent competitors.  This represents the first patent issuance in Europe under Lexaria’s first patent family.

Lexaria intends to validate and nationalize this patent in many major European countries, significantly expanding our global reach. This patent is a significant addition to the Lexaria intellectual property portfolio, and toward Lexaria’s first formal patent protection across major European nations covering a population of roughly 340 million people.

“We’re very pleased to be awarded our very first European patent grant as we’re continually working to expand both the geography where Lexaria’s intellectual property is protected under law, as well as expand the scope of business possible,” said Chris Bunka, Lexaria Chief Executive Officer. “The receipt of this patent grant is timely in that we have recently forged new relationships in Europe where a number of countries have very progressive markets for the oral delivery of active substances including nicotine and more, supporting our commercialization efforts.”

Lexaria currently has 18 granted patents (including nine granted in the US), along with approximately 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Pending patents are for the delivery of many antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more.
 
About Lexaria

Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a federally licensed research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit        www.lexariabioscience.com.

 
FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, all statements by the company related to patents granted or pending. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements.  As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling products containing any active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful or defensible. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).  Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
 
Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

INVESTOR CONTACT:
ir@lexariabioscience.com
Phone: 866-221-3341
 
Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC V1X 2P7.

www.lexariabioscience.com

$LXRP ---


NEWS RELEASE

https://virtual-strategy.com/2020/10/13/lexaria-bioscience-advances-antiviral-research-initiative-using-dehydratech/


The Oral Bioavailability Problem While a host of antiviral drugs exist or are under development today, many of them are hindered by poor water solubility which, in turn, results in their poor absorption and uptake by the body if taken orally. The reason for this is because the human gastrointestinal system is designed to absorb nutrients and other ingested compounds that are primarily water soluble rather than fat soluble or “lipophilic.” And, compounding this problem, the human gastrointestinal system is further designed to channel most compounds it absorbs through the liver for detoxification prior to entry into the bloodstream, which functions as another absorption impediment for many antiviral drugs if taken orally. In concert, these physiological limitations can result in low oral bioavailability for many antiviral drugs, interfering with how well they can reach the bloodstream after ingestion and, in turn, frequently limiting their overall therapeutic effectiveness (Ford et al., 2020).

To attempt to overcome this, oral antiviral medications often have to be given at high doses which can result in a variety of unwanted side effects including diarrhea, headache, nausea, vomiting, stomach upset, drowsiness, dizziness, vision changes, difficulty breathing and other bodily dysfunctions.

Alternatively, in some cases it is necessary to administer antiviral medications by way of needle injection for easier access to the bloodstream circumventing the gastrointestinal absorption limitations. Remdesivir is one such example of an antiviral medication administered by injection instead of orally for this reason. However, injectable administration requires involvement of a medical practitioner which may not be easily accessible for the masses, usually increases cost of a medicine and often means that the product format isn’t as stable or requires special storage and handling considerations relative to oral medications.

Introducing DehydraTECH™ – Effective Oral Delivery for Poorly Water Soluble Drugs DehydraTECH is a patented formulation processing technology developed by Lexaria Bioscience Corp. and licensed to its wholly owned subsidiary Lexaria Pharmaceutical Corp. that has been shown to enhance the performance of lipophilic drugs in oral ingestible products by way of increased rate and extent of intestinal bioabsorption and delivery to target tissues.

DehydraTECH is believed to accomplish this by effecting a temporary molecular association between a given drug compound of interest and certain long chain triglyceride (LCT) ingestible oils, such as oleic acid rich sunflower oil, so that the physiological absorption benefits of the LCTs are conferred upon the drug compound. In particular, LCTs are known to be absorbed intestinally by a specialized process in concert with biliary excretions in the human gut that results in their rapid channeling into the bloodstream bypassing metabolism by the liver (Zgair et al., 2016; Reddy and Murthy, 2002).

In short, DehydraTECH is thought to enable delivery of lipophilic drugs in effect as “payload” compounds in tow with the LCTs that power DehydraTECH formulations. DehydraTECH formulations have been prepared with a range of lipophilic beneficial molecules of interest and administered orally to animals and humans to investigate their absorption and pharmacological performance enhancing attributes. Active ingredients formulated and/or evaluated to date with the DehydraTECH technology have included cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol, terpenoids, nicotine polacrilex, ibuprofen, geraniol, catachin and sildenafil citrate. For example, oral DehydraTECH formulations of CBD have been studied demonstrating as high as an 811% increase in CBD blood perfusion in animals overall and as high as a 317% increase within the first 30 minutes of administration in human volunteers without any safety or tolerability concerns (Patrician et al., 2019).

DehydraTECH™ Antiviral Research Underway Based on Lexaria’s success to date in developing and commercializing DehydraTECH oral product formats for other lipophilic drug compounds, is actively investigating its prospective utility to improve the bioavailability of antiviral drug candidates.

Studies underway and/or in the planning stages include pilot testing in human volunteers to determine the rate and extent of bioavailability enhancement for certain repurposed antiviral medications upon oral administration, as well as testing to follow that will evaluate if this translates into increased effectiveness against SARS-CoV-2 and/or other infections in appropriate laboratory and animal models.

If successful, the Company intends to make its DehydraTECH technology available to prospective research partners throughout the world looking to maximize the effectiveness of their own drug investigations with a view to enabling development of safe, effective and readily commercially accessible/viable oral antiviral medications against COVID-19 and other infectious diseases, whether for 4 repurposed existing drugs and/or for new emerging drug candidates. Furthermore, as noted above, Lexaria has previously demonstrated utility of its DehydraTECH technology for formulating drugs with known anti-inflammatory properties like non-steroidal anti-inflammatory drugs and CBD. Therefore, the Company also envisions its technology being useful for the development of multi-pronged therapeutic strategies for COVID-19 and other infectious diseases where reduction in viral load together with mitigation of the human innate immunological inflammatory response may be necessary in concert to improve therapeutic outcomes for patients.

Conclusion

In summary, Lexaria believes that its DehydraTECH technology has the potential to significantly increase bioavailability for many oral antiviral medications. This, in turn, is expected to make oral antiviral drugs work more effectively for better therapeutic outcomes and at lower doses than are otherwise necessary in order to minimize unwanted side effects. Furthermore, this may also make the oral route of administration a viable alternative to injection for certain antiviral medications which could lead to better cost effectiveness and wider availability without the added complexity of formulating and administering injectable preparations.

Finally, Lexaria believes that its DehydraTECH technology has the added potential to help treat serious viral conditions like COVID-19 by enabling improved anti-inflammatory drug delivery and effectiveness, which may prove to be of critical importance to decrease disease severity together with reducing viral load with antiviral therapies.


 https://get.ceo3in60.com/lxrp/

Good Post Alexulf. Lexaria has many irons in the fire, and if just one strikes, we are off to the races. I like the idea that companies in tobacco (five majors), big pharma (pretty much all majors), beverages (alcohol, sweet and sparkling water), candies and edibles, and finally CBD and THC products. I am not certain if I missed anything, but you get the idea. The future is wide open for DehydraTech adoption in hundreds of products and scores of industries.

Unvctrader9m, I do not have a problem with any of the points you brought up. Univec is a dark and non-reporting company, and Doctor Dalton filed to become just that. This is why you do not see direct information posted. As for Teva Pharmaceuticals, that information is months old. It is absolutely true, but it has been public for a very long time. I prefaced my first post by saying "I do not know" because I cannot tell you for certain if Mitchell will be a part of UNVC or not. I can only tell you that Mitchell was part of the old AGRiMED company, and Doctor Dalton did want Mitchell involved at one time.

A new product now available for order from Doctor Mitchell. This flyer comes with pictures, but I do not have that ability for posting. While we do not know if Mitchell will be part of Univec Conglomerate, this product is a true game changer. This is just one of some 13 additional products available by mid-April (this particular product is available for order right now).


2-PATH SALES SHEET

VitaminCBD™ Dual Pathway in its Fight against Anxiety 2020

Hemp Commodity Industries, LLC (HCI) VitaminCBD™ is Maine’s own organic hemp lifestyle retailer. Nature Inspired-Medically Researched-Patient Tested- VitaminCBD™ is one of Maine’s leading health and wellness hemp retailers. A new formulation for an age-old problem. ANXIETY!

Inspired by our medical and agricultural roots, our labs blend powerful ingredients drawn from nature and science to create affordable lifestyle wellness products. Nature inspired. Third-party tested.

There are two pathways used in this new formulation. Both of these different pathways are used to counter inflammation and anxiety. Both pathways are being activated by way of the Cannabinoid Pathway in two different ways, a major piece of overlooked research until now.

The first pathway operates as an acid form from the main precursor CBG-A. CBD-A has been somewhat overlooked with societies rush to get to CBD. CBD-A is normally found in the raw cannabis plant in low concentrations and is often suggested to chew raw hemp to get this very special benefit. CBD-A is a powerful Cox2 inhibitor with exponential power over serotonin receptors compared to CBD and all its recent rage!

The second pathway is a neutrally charged Cannabinoid known as CBD. CBD works on the Endocannabinoid System (ECS) with CB1 and CB2 receptors. Both of these pathways with our new special formulation gives us a new tincture with a major emphasis that may help to fight anxiety in these trying times of COVID-19.



Kgem

Unvctrader9m, I cannot answer these questions, but I never did make these claims. I suggest you ask those who did make these claims, and ask them for specifics. As for the Nigerian team. I never did pay much attention to them because all they seem to do is repeat what others have already posted. Also, I do not understand them half or more of the time --- I don't even know how many of them there are (it seems more names pop up all the time).

BeerIsGood, I can tell you that one can call both of these companies, but I am not certain how one can call them directly (put it this way, I never tried to call them directly). I called Dalton's number about a year ago when I had a problem with a medication, and he answered at PPSI. Dalton did not pick up the phone himself. Instead, I found he had a large office at PPSI, a staff of at least six or seven (they were together in a conference room when I called), and when I actually was transferred to Dalton he told me he was working in his lab. Dalton apparently has a fully staffed lab at PPSI where he works on and develops medications himself.

Another excellent question Unvctrader9m. I don't know why Dalton is stilling keeping everything quiet about his companies --- other than the fact that he filed to become dark and non-reporting, and he claims he is doing so while he is working to pull everything together. I also know that start-up pharmaceutical companies can spend around a million dollars a year to defend their products and patents. Large pharmaceutical companies seem to enjoy bogging down small companies with lawsuits in the hope of driving them out of business. I suspect this is the reason he is so secretive. In the ten years since he filed to become dark, he could easily have saved (at least) ten million dollars.

BeerIsGood, that is an excellent question. As for the answer, I am going by the tweets and LinkedIn posts Doctor Dalton made numerous times. Dalton says he helped design the modern pharmacy system that utilizes his ordering, billing, script identification, and prescribing system as well as insurance recommendations. I do not know the name of his software system. As for the syringes, I don't know for certain that he still is making them either, but Dalton's comments at IFAH last year certainly seemed to indicate that we are. And doing so in conjunction with a program run by John's Hopkins. Why can't we prove it? I suggest we cannot prove it because the syringe business is likely run within PPSI or HRI or both, and they are currently private companies.

Good Morning All. Well, my city is on shut down and the streets are like a ghost town. This city is a college town with three universities and students from all over the world. We also have a large hospital that services much of the state. This means we do have the corona virus (not too many cases currently reported) in our city.

With that statement out of the way, I must tell Univec investors that this virus has got to be a big help for us. First, Dalton is a pharmacist with an entire network of pharmacies all working with our ordering and billing software. In fact, our software actually helps or suggests medications and then helps doctors and pharmacists maximize their payment by implementing billing procedures searching out the best payment options. So our software system will see heavy demand during this time of crisis. Remember, Univec is so much more than cannabis.

Second, the FDA and Medicaid and all government agencies are slashing red tape and streamlining processes to speed up approvals. So this should help us too.

While we do not know when Dalton will finally pull the trigger, I suspect this whole virus crisis will speed that date and outcome. I look forward to the time when all of us will be happy with our account numbers, and I intend to spend some of that money when we are off of lockdown.

Be Safe, and Be Well.


Kgem

Very good question BeerIsGood. I have seen this reference before and HRI is mentioned in their description of services (dental offices use pharmaceutical services also). Although your question seems to revolve around the location given, I personally do not see that as a problem. Doctor Dalton has more then one business location even today.

I do remember seeing a reference to dental services in an old biography, but I cannot find it right now. Once again, you bring up a very good question and if I can locate the old biography where I seen this reference, I will post it. Right now I am still looking.

BeerIsGood, I cannot answer privately to your questions regarding Doctor Dalton and Univec. However, I can say that some of these questions were answered by Dalton. All be it a while ago. I cannot blame you for asking serious questions, and no one should. For myself, I don't see the possibility of combining large cap companies with small cap sub penny companies either --- lawsuits would ensue by banks, mutual funds, and wealthy stockholders. However, a partnership is not a merger. So some flexibility is possible in my opinion. The same is true for joint ventures. It would be speculation on my part, but why wouldn't a large company just buy the smaller company? At the same time, I do not believe Dalton has selling in mind. Doctor Dalton has always spoke in terms of building a legacy, and that suggests that selling is not an option for him.

The latest essay written by Doctor Eric I. Mitchell who may or may not be involved with Univec. Mitchell wrote this article to address current concerns involving the corona virus.

VitaminCBD™ at War with COVID-19
The Influenza of 1918—The Face of Anxiety


102 Years ago, the world, planet earth was at war with its neighbors and the Spanish Flu was alive and well. I’m being a bit glib because that virus killed more people around the world than that long protracted world war. As a student of history, there is a great short story which tells the tale of two cities and how each reacted to that Pandemic and the parallels I want to make about VitaminCBD™ then and now.

The two cities were Philadelphia and St. Louis. This was 1918, and the influenza was raging around the world. There were ships pulling into the harbor of the Philadelphia port with sailors from other ports. There was a parade planned for liberty stamps to support the war. A number of public health officials recommended that this parade be canceled because of concerns about containment of this virus. It was determined by City Hall that the parade would go on, a major mistake. The day that St Louis had their first influenza death, quarantine of the city went into full effect. In Philadelphia, it took 14 days after its first death for Philadelphia to go into quarantine, second very, very big mistake.

The death rate for St Louis was 63 per one hundred thousand. Philadelphia’s death rate was 246 people per one hundred thousand. Bodies in Philadelphia were piled in the streets, big difference. I am not drawing a present day parallel to these two cities. I am mainly using this story to take us back to that space in time because COVID-19 is running our lives at the moment and there is another lesson to be learned from the past of how our grandparents and great grandparents weathered the storm of anxiety.

One in thirteen people around the world live with an anxiety disorder, making it the most common mental health disorder worldwide, according to the World Health Organization (WHO). For those living with anxiety, finding a safe method for managing symptoms is a critical concern.

If you’re curious about using VitaminCBD™ oil as a tool to help manage your anxiety, education is critical. Understanding the pros and cons of the various ingestion methods can help you determine which form of consumption best suits your needs and why it is important for the Endocannabinoid System (ECS). Yes, feeding the ECS is critical and most of us are deficient in the principal Cannabinoids (CBD, CBG, CBN).

However, after the 1937 prohibition on hemp, the Marijuana Tax Act of 1937 and the industrial revolution which resulted in over-farming of our lands, our exogenous phytocannabinoid supply fell into dietary neglect as our bodies make two phytocannabinoids, but often not enough.

As most scientists and clinicians will readily admit today, there is no universally recommended dosage for CBD, however, it is clear that phytocannabinoids (Cannabinoids) are necessary today, as much as in 1918, for our homeostatic ECS System which helps to balance our much-needed immune system. In 1918, hemp and its phytocannabinoid elements were part of our daily diet found in our food source.




To date, there haven’t been any large-scale clinical trials to inform dosage guidelines in supplying cannabinoids for the ECS. However, over the last seven years I continue to go with the concept of start slow and go low, 15mg/ml up to 50mg/ml is the starting range relative to body weight and pain level. In addition, the FDA is still learning about CBD—such as its cumulative effects on the body—before it decides on how to regulate it.

This doesn’t necessarily mean VitaminCBD™ is unsafe. Existing research already suggests that it appears to be a safe, well-tolerated treatment for longer than modern medicine. If you’re interested in experimenting with CBD to manage your anxiety symptoms with this War on COVID-19, - you can PM me and I will share my knowledge and my cautious approach to dosing (which is always a good idea). You can also go to www.VitaminCBD.life. I have experience from seed to formulation to sales of VitaminCBD™, and 40-plus years medical background so I can help!

We all know what it feels like to “stress out” before an exam or important event. But, sometimes a challenging job, family demands, or just surviving the unexpected events of life can feel like a continual test and now add Covid-19 to your equation. If that impending sense of disaster is never-ending, it's a sign of anxiety and supporting your ECS with VitaminCBD™ may be your answer as CBD was for your grandparents.

Authored by

Eric I. Mitchell MD MA FACPE CPE

Hello All Univec shareholders. Let me just say that something is definitely happening with our various partners, and telehealth is one of the hottest areas of the market right now. While I do not claim to understand how a company with shares trading at over a hundred dollars per share and trading with only 73 million authorized shares can merge with a sub-penny company with 1.2 billion shares, a partnership of some sort may be possible in today’s world.

However, a partnership (if that is what we have) is still not a merger, and we should not confuse the two.

With this first issue out of the way, we should discuss another. Doctor Dalton was at one time involved with the insurance industry, and had his own dental insurance which he ran in conjunction with Paramount Insurance. I cannot say if Dalton is still involved in the insurance industry, but if so, then he could benefit from that surge during the corona virus as well.

Finally, pharmaceutical services. Pharmaceutical services is the area most needed during our current health crisis. This is where testing and analytics takes place, and it includes all the chemicals and reagents needed to test and analyze medical samples. In my opinion, this industry is about to surge as the corona virus surges.

While I dislike talking about monetary gain during times like these, the fact is we just might be in the right place and at the right time. Everything is about to speed up big time, and Dalton might move up his time frame as well.

Good luck and good fortune to all of us invested in Univec. Dalton just might have seen or perhaps gleaned this moment coming, and we will all now benefit from his possible foreknowledge.

Kgem

The latest essay written by Doctor Eric I. Mitchell (once again, we do not know what or even if Doctor Mitchell will have any roll to play in the Univec Conglomerate). Doctor Mitchell does grow medical cannabis, he does have products, and he does have clinical trials ongoing). At one time, Doctor Mitchell was the Medical Director at AGRiMED when that company was in operation, and Doctor Mitchell interviewed and appointed Doctor Dalton to AGRiMED's Board of Directors.


Keeping Your Eye on the Ball--- Putting CBD-A, Step-One in the Mix


Step-one remember Step-one! This happens all the time! We jump past Step-one in our quest to find step-two in pursuit to find the answer about the effects of CBD on our Endocannabinoid System (ECS). Well, in the case of CBD, we might have stepped past one of the most important steps in the medical arena, bypassing another important human biological system. In our attempt to go from Step-one to our CBD destination, an important Enzyme Cox2 System is missed. The Godfather of Cannabis, Dr. Raphael Mechoulam, has recently warned the medical community not to go to sleep on this step-one after it took 30 years for the medical community to embrace the pathology of CBD on the ECS which is the
step-two.

Reverse engines! The first step that we are talking about is CBD-A. CBD-A is the first step, which is the acid form and precursor for the second most frequent Cannabinoid found in the Cannabis sativa L plant, CBD. This CBD-A is normally found in the raw cannabis plant in low concentrations. This CBD-A is considered unstable and with time and heat will convert to CBD. The CBD rage can stand on its own two feet with research now unleashed after the 2018 Farm Bill was enacted. But, before we go there, let’s look back at step-one, CBD-A.

“It’s an interesting molecule that potentially doesn’t have side effects,” said Dan Peer, Managing Director of the Center for Translational Medicine and head of the Cancer Biology Research Center at Tel Aviv University. Just like CBD, CBD-A is a non-psychoactive compound, so it does not cause one to get high if present in CBD products. This compound is currently being investigated for its antibacterial and anti-inflammatory properties.

CBD-A or CBD-acid is the main form in which CBD exists in the raw cannabis plant, along with THC-A (THC-acid) another blog for another point in time. CBD is obtained through a non-enzymatic decarboxylation from the acidic form CBD-A of the cannabinoid to the decarboxylated form known as CBD. This decarboxylated reaction takes place when the raw cannabis compound is heated and/or over time because it’s an unstable form, unlike CBD. The decarboxylation procedure is also called “activation”, and requires about 90 minutes of time when the cannabis infusions are heated at 212° F.

The most interesting factor about CBD-A is when it is in its acid form and nonactivated for the ECS, it’s working via another bodily pathway that we have skipped over making our way to CBD. What is that other pathway and what role does CBD-A play in our human pathology? The naturally occurring but unstable CBD acid (CBD-A) is believed to be a thousand times more potent than CBD in binding to a particular serotonin receptor thought to be responsible for alleviating nausea and anxiety and inflammation. Reducing Inflammation are the key words in disease management! “It works like a steroid. If it doesn’t have adverse effects, then you have a replacement, which is great,” Peer said, discussing testing he did with cannabis acids and inflammatory bowel disease.

Heating the plant at a lower temperature or for a shorter time may lead to partial instead of full activation; until recently, it’s been considered that this is not desirable or convenient, as it reduces the final amount of CBD obtained from a plant which has been considered the treasure trove of the cannabis plant. However, new research suggests that CBD-A may also be of great value for humans in controlling inflammation via another centralized human biological system. When this compound, CBD-A was first discovered, it was thought to be a minor cannabinoid, and most producers preferred to decarboxylate CBD-A so as to obtain higher amounts of CBD. Yet, the new emerging studies are promising, as the acidic form of cannabidiol seems to have anti-inflammatory and anti-proliferative properties.

Anti-inflammatory properties—The anti-inflammatory properties of CBD-acid seem to be the result of the inhibitory action of this compound on Cox-2 (cyclooxygenase-2), a compound involved in inflammatory processes. This mechanism is another biological pathway outside of the ECS. The Cox-2 Enzyme System is well known to the medical and pharmaceutical communities because it is a principal mechanism for our nonsteroidal medication from Motrin to Celebrex which are commonly used pharmaceutical medicines as an anti-inflammatory.

Getting two for one is the deal that usually makes us stop in our tracks and we give consideration to the value proposition that is being offered. This two for one deal CBD-A and Vitamin CBD™ in one bottle is a winner whereby we have dual biological systems working toward one collective end in fighting inflammation which is a major cause for a plethora of maladies from PTSD to IBS.


Authored by

Eric I. Mitchell, MD MA FACPE CPE

Could the current Coronavirus effect one’s investment in Univec Conglomerate and help one survive the contagion? Perhaps. Of course, Univec must first market a product to take advantage of this situation.

It should be noted that very few people make it through the winter without an annoying cold or a runny nose. Some of us will also catch the flu.

What doctors often don’t tell you is that in most cases it’s best to let colds and cases of flu run their course while using natural medication to help ease many symptoms. One of these natural remedies, CBD, can boost your immune system, preventing your body from catching these viruses in the first place. Thus, CBD can be viewed as an illness preventer.

MarijuanaBreak: CBD is known to ease many symptoms of the common cold because CBD is a potent anti-inflammatory which can fight pain, sinus pressure, and can reduce common pains associated with these viruses which allow the body to rest and self-heal. In addition, CBD has become a favorite item in recent years for its immune strengthening properties. Immune Strengthening, together with anti-inflammation capabilities, are major attributes of a daily CBD regiment (one eyedropper or even two taken daily --- usually just before bedtime or in the morning or both).

To understand how a cold affects our body, it’s important to understand that colds and flus are the outcomes of viruses commonly found within our bodies. These viruses are microscopic particles of genetic material, each coated with a thin layer of protein. Unlike the natural cells in your body, viruses are not able to reproduce on their own, but instead, use the machinery and metabolism of your own cells to produce multiple copies of themselves.

Once the virus enters a cell, it will either use that cell’s resources to replicate itself, eventually breaking or destroying the cell, or, incorporating itself into the DNA of your cell. This allows the virus to be passed down through natural genetic duplication (mitosis) and cellular division (cytokinesis).

https://www.marijuanabreak.com/doctors-wont-tell-you

The important takeaway for readers and for investors in UNVC is that a regular regiment of CBD can protect you from getting a cold and flu in the first place, and if you do contract an illness, CBD can reduce the length and severity of the illness.


Kgem

Doctor Eric I. Mitchell is coming on strong after just returning from a Florida investor’s conference now with new products and new clients. I will be listing some of these products shortly. Although it is still unknown what part Doctor Mitchell might play in this new Univec Conglomerate, his name and brand our gaining notoriety as each day goes by. Products ranging from anxiety relief for over the road truck drivers (products with zero or unmeasurable THC) to salves, creams, oils, gummies, gums, and candies. Stay tuned. Launch date is said to be the first half of this month.

Kgem

The latest article from Doctor Eric I. Mitchell. As Univec investors know, Doctor Dalton claims active clinical trials in Israel for at least the last two to two and a half years. Doctor Mitchell interviewed and then appointed Doctor Dalton to AGRiMED’s Board of Directors when that company started operations around two and a half years ago. It is unknown at this time what part (if any) Doctor Mitchell might play in the future of Univec Conglomerate.

Keeping Your Eye on the Ball Putting CBD-A in the Mix Step one, remember step one! This happens all the time! We jump past step one in our quest to find step two in pursuit to find the answer about the effects of the Cannabinoid, CBD, on our Endocannabinoid System (ECS). Well, in the case of CBD we might have stepped past one of the most important steps in the medical arena bypassing another important biological system on the way to our destination to power the ECS. The Godfather of Cannabis, Dr. Raphael Mechoulam recently warned the medical community not to go to sleep on this step one after it took 30 years for the medical community to embrace the pathology of CBD on the ECS which was the step two.

Reverse engines! The first step that we are talking about is CBD-A. CBD-A is the first step, which is the acid form and precursor for the second most frequent Cannabinoid found in the Cannabis sativa L plant, CBD. This CBD-A is normally found in the raw cannabis plant in low concentrations. CBD-A is considered to be unstable and with time and heat will convert to CBD. The CBD rage can stand on its own feet with research now unleashed after the 2018 Farm Bill. But, before we go there, let’s look closer at step one, CBD-A.

“It’s (CBD-A) an interesting molecule that potentially doesn’t have side effects,” said Dan Peer, Managing Director of the Center for Translational Medicine and head of the Cancer Biology Research Center at Tel Aviv University. Just like CBD, CBD-A is a non-psychoactive compound, so it does not cause one to get high if present in CBD products. This CBD-A compound is currently being investigated for its antibacterial and anti-inflammatory properties.

CBD-A or CBD-acid is the main form in which CBD exists in the raw cannabis plant, along with THC-A (THC-acid). CBD is then obtained through a non-enzymatic decarboxylation from the acidic form CBD-A to the Cannabinoid, CBD, this reaction taking place when the compound is heated. The decarboxylation procedure is also called “activation,” and requires about 90 minutes when the cannabis infusions are heated to 212° F. The naturally occurring but unstable CBD acid (CBDA) is believed to be a thousand times more potent than CBD in binding to particular serotonin receptors thought to be responsible for alleviating nausea and anxiety.

The most interesting factor about CBD-A is when it is in its acid form and non-activated for the ECS, it’s working via another bodily pathway that we skipped over while making our way to CBD. What is that other pathway and what role does CBD-A play in our human pathology? Inflammation is the key word! “It (CBD-A) works like a steroid. If it doesn’t have adverse effects, then you have a replacement, which is great,” Peer said, discussing testing he did with cannabis acids and inflammatory bowel disease.

Heating the plant at a lower temperature or for a shorter time may lead to partial instead of full activation; until recently, it’s been considered that this is not desirable or convenient, as it reduces the final amount of CBD obtained from a plant. However, new research suggests that CBD-A may also be of great value for humans. When this compound was first discovered, it was thought to be a minor cannabinoid, and most producers preferred to decarboxylate CBD-A so as to obtain higher amounts of CBD. Yet, the existing studies are promising, as the acidic form of cannabidiol seems to have anti-inflammatory and anti-proliferative properties (this means CBD-A has cancer fighting attributes).

Anti-inflammatory properties–The anti-inflammatory properties of CBD-acid seem to be the result of the inhibitory action of this compound on COX-2 (cyclooxygenase-2), a compound involved in inflammatory processes. This mechanism is another pathway outside of the ECS. In another study, a team of scientists led by Israeli chemist, Raphael Mechoulam, identified wake-promoting effects of cannabidiolic acid (CBD-A) in rats. They studied CBD-A indirectly by using a more stable synthetic version of the cannabinoid produced in Dr. Mechoulam’s lab. Administration of CBD-A increased wakefulness by around 50% by decreasing the amount of time the rats spent in slow-wave sleep without impacting time spent in the REM sleep stage (i.e., when humans experience vivid dreams). These effects were associated with increased levels of wake-promoting brain chemicals such as acetylcholine that helps promote attention in awake animals. In plain English, this means the individual becomes more alert and more aware of what is happening around them.

Important note: The stability of CBD-A may lead to a number of clinical applications in the near future. There is research currently being done that is looking at ratios of CBD-A to CBD. Some preliminary results are showing a marked increase in clinical efficacy by using these two cannabinoids that work through two different pathological mechanisms. We must keep our “eye on the ball” as we put CBD-A into the mix in fighting inflammation through two different pathways at the same time. Doctor Mitchell has an active clinical experiment ongoing at the time of this writing to exploit step one, elevating concentrations of CBDA as we continue to relish the positive clinical applications of step two, CBD.

Eric I. Mitchell, MD MA FACPE CPE